Home > Resources > Whitepapers > Detection of immune checkpoint markers in peripheral blood mononuclear cell lysates with AlphaLISA

Detection of immune checkpoint markers in peripheral blood mononuclear cell lysates with AlphaLISA

September 19, 2018

Peripheral blood mononuclear cells (PBMCs) are a heterogeneous the population of blood cells having round nuclei. They consist of monocytes, macrophages, dendritic cells and lymphocytes (T cells, B cells, and NK cells). In order to induce and upregulate the expression of specific immune checkpoint markers in the PBMC populations, we used Dynabeads®, polystyrene-coated microspheres with antibodies against human CD3 and CD28 proteins covalently coupled to the surface.

Spotlight

Medley Medical Solutions Private Limited

Medleymed seeks to reimagine healthcare for the new age - with the patient at the centre. Our vision is to harness the power of technology to orchestrate the complex healthcare value chain for the benefit of patients. As an innovative start-up, promoted by a leading IT Company and led by a young team of thinkers and doers, we operate at the cutting edge of technology and health.

OTHER WHITEPAPERS

The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins